Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Systemic lupus erythematosus (SLE) is the most common form of lupus. It is an autoimmune disease in which the body’s immune system mistakenly attacks its own healthy cells and organs, leading to inflammation and damage (Centers for Disease Control and Prevention, 2024). SLE is a chronic disease that can affect the skin, joints, blood, and organs such as the kidneys, lungs, and heart. There is currently no cure for SLE, but it can be treated. LN is one of the most serious complications of SLE and often develops within five years of when SLE symptoms first appear (Lupus Foundation of America, 2021).

The symptoms of SLE are joint pain and stiffness throughout the body, fatigue, rashes, and swollen glands, among others. The most common sign of SLE is a red, butterfly-shaped rash over the cheeks and nose that can appear after exposure to sunlight (Mayo Clinic, 2022). The exact cause of SLE is unknown, but scientists believe that certain factors, such as hormones, genetics, and environment, trigger lupus (Centers for Disease Control and Prevention, 2024; Mayo Clinic, 2022). Most SLE patients experience flares – when signs and symptoms get worse for a period and then improve or disappear for some time (Mayo Clinic, 2022). Lupus nephritis (LN) is the most serious complication of SLE. LN develops when lupus antibodies affect the kidneys, causing swelling, irritation, and possible organ damage. LN can damage the kidney’s ability to remove waste from the blood and can lead to blood in urine, protein in the urine, high blood pressure, or kidney failure (Mayo Clinic, 2025).

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SLE and LN in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SLE and LN. The diagnosed prevalent cases of SLE and LN are segmented by age and sex. The diagnosed prevalent cases of SLE are also segmented by severity, and the diagnosed prevalent cases of LN are further segmented by class. This epidemiology forecast for SLE and LN is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident and prevalent cases of SLE and LN across these markets.

Reasons to Buy

The Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) series will allow you to –

Develop business strategies by understanding the trends shaping and driving the global SLE and LN markets.

Quantify patient populations in the global SLE and LN markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SLE and LN therapeutics in each of the markets covered.

Understand magnitude of the SLE and LN population by age, sex, SLE severity and LN class.

Table of Contents

Contents

List of Tables

List of Figures

About GlobalData

1 Systemic Lupus Erythematosus and Lupus Nephritis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of SLE

2.4.4 Forecast assumptions and methods: Diagnosed prevalent cases of SLE by severity

2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of LN

2.4.6 Diagnosed prevalent cases of LN by Class

2.5 Epidemiological forecast for diagnosed prevalent cases of SLE (2024–34)

2.5.1 Diagnosed prevalent cases of SLE

2.5.2 Age-specific diagnosed prevalent cases of SLE

2.5.3 Sex-specific diagnosed prevalent cases of SLE

2.5.4 Diagnosed prevalent cases of SLE by severity

2.5.5 Diagnosed prevalent cases of LN

2.5.6 Age-specific diagnosed prevalent cases of LN

2.5.7 Sex-specific diagnosed prevalent cases of LN

2.5.8 Diagnosed prevalent cases of LN by class

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Vice President of Disease Analysis and Intelligence

3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence

Contact Us

Table

Table 1: Summary of newly added or removed data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for SLE

Figures

Figure 1: 7MM, diagnosed prevalent cases of SLE, both sexes, N, all ages, 2024 and 2034

Figure 2: 7MM, diagnosed prevalent cases of LN, both sexes, N, all ages, 2024 and 2034

Figure 3: 7MM, diagnosed prevalence of SLE, men, women, %, all ages, 2024

Figure 4: 7MM, diagnosed prevalence of LN, men, women, %, all ages, 2024

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of SLE

Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of SLE by severity

Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of LN

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of LN by class

Figure 9: 7MM, diagnosed prevalent cases of SLE, N, both sexes, all ages, 2024

Figure 10: 7MM, diagnosed prevalent cases of SLE by age, N, both sexes, 2024

Figure 11: 7MM, diagnosed prevalent cases of SLE by sex, N, all ages, 2024

Figure 12: 7MM, diagnosed prevalent cases of SLE by severity, N, both sexes, all ages, 2024

Figure 13: 7MM, diagnosed prevalent cases of LN, N, both sexes, all ages, 2024

Figure 14: 7MM, diagnosed prevalent cases of LN by age, N, both sexes, all ages, 2024

Figure 15: 7MM, diagnosed prevalent cases of LN by sex, N, men, women, all ages, 2024

Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma, Q4 2025
$795 | January 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma, Q4 2025
$795 | January 2026
Pharmaceuticals
New
Biocomputing: Market Trends and Innovations
$995 | January 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034 in real time.

  • Access a live Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.